Teva Sees 2015 Profit Above Estimates on Generic Delay
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd.’s 2015 profit may surpass analyst estimates if generic copies of bestselling multiple sclerosis drug Copaxone are kept off the market until September.
Earnings excluding some costs will be $5 to $5.30 per American depositary receipt in a scenario with two generic versions of once-a-day Copaxone in September, Teva said in a statement today. Analysts predict $5.05 on average with some of the 19 estimates factoring in copycat competition and others not.